Tiziana Life Sciences (TLSA) Expected to Post Quarterly Earnings on Friday

Key Points

• Tiziana Life Sciences is expected to report quarterly results before Friday’s market open, with analysts forecasting a loss of $0.0783 per share.
• TLSA shares opened at $0.96, below their 50-day and 200-day moving averages, and are trading near the lower end of their 52-week range of $0.87 to $2.35.
• Insiders have recently increased their holdings, including CEO Ivor Elrifi’s purchase of 667,000 shares; analyst sentiment remains mixed, with one Buy, one Hold, and one Sell rating, resulting in an overall “Hold” consensus.

Tiziana Life Sciences (NASDAQ:TLSA - Get Free Report) is expected to be announcing its results before the market opens on Friday, September 18th. Analysts expect Tiziana Life Sciences to announce earnings of ($0.0783) per share for the quarter.

Tiziana Life Sciences Trading Down 1.3%

Shares of NASDAQ:TLSA opened at $0.96 on Friday. The business's fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.22. Tiziana Life Sciences has a fifty-two week low of $0.87 and a fifty-two week high of $2.35.

Insider Transactions at Tiziana Life Sciences

In other Tiziana Life Sciences news, CEO Ivor Elrifi acquired 667,000 shares of the business's stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $1.00 per share, for a total transaction of $667,000.00. Following the transaction, the chief executive officer owned 4,472,261 shares in the company, valued at $4,472,261. This trade represents a 17.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders acquired 988,423 shares of company stock valued at $985,909. Insiders own 39.82% of the company's stock.

Institutional Trading of Tiziana Life Sciences

Large investors have recently made changes to their positions in the business. Bison Wealth LLC acquired a new position in Tiziana Life Sciences during the 4th quarter worth about $30,000. Cubist Systematic Strategies LLC acquired a new position in shares of Tiziana Life Sciences during the first quarter worth approximately $25,000. Jane Street Group LLC lifted its position in shares of Tiziana Life Sciences by 968.2% during the first quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after purchasing an additional 151,858 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Tiziana Life Sciences during the second quarter valued at approximately $39,000. Finally, Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences during the third quarter valued at approximately $520,000.

Analyst Ratings Changes

TLSA has been the topic of several recent analyst reports. BTIG Research started coverage on shares of Tiziana Life Sciences in a research note on Thursday, September 3rd. They issued a "buy" rating on the stock. Zacks Research raised shares of Tiziana Life Sciences to a "hold" rating in a report on Tuesday, July 14th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Tiziana Life Sciences in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold".

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc NASDAQ: TLSA is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.